TriSalus Life Sciences (NASDAQ:TLSIW) Shares Up 4.5% – Time to Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s share price traded up 4.5% during mid-day trading on Thursday . The company traded as high as $0.65 and last traded at $0.6790. 2,983 shares changed hands during trading, a decline of 44% from the average session volume of 5,330 shares. The stock had previously closed at $0.65.

TriSalus Life Sciences Price Performance

The firm’s 50 day moving average price is $0.77 and its two-hundred day moving average price is $1.16.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $1,374,000. Citadel Advisors LLC grew its stake in shares of TriSalus Life Sciences by 439.0% in the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after buying an additional 103,336 shares during the period. Aristeia Capital L.L.C. acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter valued at about $43,000. Finally, Fort Baker Capital Management LP bought a new stake in TriSalus Life Sciences in the 4th quarter valued at about $44,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.